ProMIS Neurosciences Inc. (PMN) shareholders
Close on Nov 17, 2026Market cap $28.79MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jonathan Shafmaster Joint filing with Shaf QIC LLC (10.01%) | 10,534,639 | 10.01% | 13G (passive) amendment | Jul 29, 2025 |
| Jeremy M. Sclar Joint filing with Jeremy M. Sclar 2012 Irrevocable Family Trust (13.60%) | 9,511,930 | 16.90% | 13G (passive) amendment | Sep 30, 2025 |
| Ally Bridge MedAlpha Master Fund L.P. Joint filing with ABG Management Ltd. (11.30%), Ally Bridge Group (NY) LLC (11.30%) and 1 more | 6,070,405 | 11.30% | 13D (active) amendment | Jan 29, 2026 |
| Title 19 Promis Joint filing with Michael S. Gordon (9.00%) | 4,886,108 | 9.00% | 13G (passive) amendment | Jun 30, 2025 |
| Dr. Jeffrey R. Jay, M.D. Joint filing with Great Point Partners, LLC (9.99%), Ms. Lillian Nordahl (9.99%) | 3,334,520 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Sphera Funds Management Ltd. Joint filing with Sphera Global Healthcare GP Ltd. (5.51%), Sphera Global Healthcare Management LP. (5.51%) | 3,122,090 | 5.51% | 13G (passive) amendment | Sep 30, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (7.68%) | 2,509,977 | 7.68% | 13G (passive) amendment | Dec 31, 2024 |
| Fan Yu Joint filing with ABG V-SIV IX Limited (7.10%), Ally Bridge Group Global Life Science Capital Partners V, L.P. (7.10%) and 5 more | 1,644,397 | 17.00% | 13D (active) amendment | Feb 3, 2026 |
| Janus Henderson Group PLC | 1,292,757 | 14.40% | 13G (passive) | Mar 31, 2026 |
| Trails Edge Biotechnology Master Fund, LP Joint filing with Trails Edge Capital Partners, LP (9.90%), Ortav Yehudai (9.90%) | 933,477 | 9.90% | 13G (passive) | Feb 3, 2026 |
| Deep Track Capital, LP Joint filing with David Kroin (9.99%), Deep Track Biotechnology Master Fund, Ltd. (7.79%) | 902,561 | 9.99% | 13G (passive) | Jan 30, 2026 |
| Great Point Partners, LLC Joint filing with Dr. Jeffrey R. Jay, M.D. (7.66%), Ms. Lillian Nordahl (7.66%) | 736,881 | 7.66% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (7.80%), Wellington Group Holdings LLP (7.80%) and 1 more | 696,378 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 696,378 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Ms. Lillian Nordahl Joint filing with Great Point Partners, LLC (9.99%), Dr. Jeffrey R. Jay, M.D. (9.99%) | 409,648 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Sphera Global Healthcare Management LP. Joint filing with Sphera Funds Management Ltd. (7.78%), Sphera Global Healthcare GP Ltd. (7.78%) | 180,698 | 7.78% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PMN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 1,292,757 | 14.42% | $17.01M | New | 0.01% |
| Deep Track Capital, LP | 835,655 | 9.32% | $11.00M | – | 0.16% |
| Wellington Management Group Llp | 696,378 | 7.77% | $9.16M | – | 0.00% |
| Ally Bridge Group (NY) LLC | 620,319 | 6.92% | $8.16M | +206,100 | 7.22% |
| Trails Edge Capital Partners, LP | 557,103 | 6.21% | $7.33M | – | 1.16% |
| Woodline Partners LP | 441,911 | 4.93% | $5.82M | +46,616 | 0.02% |
| Yu Fan | 329,760 | 3.68% | $4.34M | – | 4.02% |
| Sphera Funds Management Ltd. | 325,591 | 3.63% | $4.28M | – | 0.56% |
| Squadron Capital Management LLC | 324,977 | 3.62% | $4.28M | – | 1.33% |
| Ikarian Capital, LLC | 205,000 | 2.29% | $2.70M | +150,000 | 0.29% |
| Ameriprise Financial Inc | 185,700 | 2.07% | $2.44M | New | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 164,275 | 1.83% | $2.16M | +25,000 | 0.00% |
| 683 Capital Management, LLC | 95,000 | 1.06% | $1.25M | +2,150 | 0.06% |
| ADAR1 Capital Management, LLC | 92,850 | 1.04% | $1.22M | −2,500 | 0.06% |
| Great Point Partners LLC | 86,150 | 0.96% | $1.13M | −285,252 | 0.21% |
| Boothbay Fund Management, LLC | 62,078 | 0.69% | $816.95K | +46,035 | 0.01% |
| Millennium Management LLC | 56,045 | 0.62% | $737.55K | −21,876 | 0.00% |
| Bank Of Montreal /Can/ | 11,371 | 0.13% | $149.64K | New | 0.00% |
| Seven Fleet Capital Management LP | 10,600 | 0.12% | $139.50K | – | 0.02% |
| Morgan Stanley | 7,559 | 0.08% | $99.48K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 6M | 71.4% | 5 / 6 | 6 / 2 | 2M | 0M |
| Q1 2026 | 25 | 6M | 68.5% | 18 / 3 | 3 / 2 | 6M | 0M |
| Q4 2025 | 9 | 0M | 3.0% | 2 / 2 | 3 / 16 | 0M | 0M |
| Q3 2025 | 23 | 0M | 4.5% | 8 / 4 | 2 / 3 | 0M | 0M |
| Q2 2025 | 19 | 0M | 3.8% | 6 / 2 | 4 / 3 | 0M | 0M |
| Q1 2025 | 16 | 0M | 4.2% | 1 / 2 | 4 / 3 | 0M | 0M |
| Q4 2024 | 18 | 0M | 4.3% | 2 / 1 | 5 / 2 | 0M | 0M |
| Q3 2024 | 18 | 0M | 4.5% | 5 / 5 | 1 / 3 | 0M | 0M |
| Q2 2024 | 16 | 0M | 1.5% | 2 / 0 | 3 / 2 | 0M | 0M |
| Q1 2024 | 16 | 0M | 1.5% | 4 / 0 | 4 / 3 | 0M | 0M |
| Q4 2023 | 15 | 0M | 1.5% | 1 / 3 | 1 / 0 | 0M | 0M |
| Q3 2023 | 14 | 0M | 1.3% | 3 / 1 | 5 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
2 funds held PMN in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PMN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 5,676 | 0.06% | $61.36K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -404 | -0.00% | -$5.32K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neil Cashman | Chief Scientific Officer, Director | 19,318 | 0.22% | Nov 3, 2026 |
| Neil K. Warma | Chief Executive Officer, Director | 6,183 | 0.07% | May 22, 2026 |
| Ivana Rubino | Chief Commercial Officer | – | – | Oct 6, 2026 |
| Johanne Kaplan | Chief Development Officer | 6,221 | 0.07% | Aug 7, 2026 |
| Max A. Milbury | Principal Accounting Officer | 8,409 | 0.09% | May 22, 2026 |
| Larry Douglas Altstiel | Chief Medical Officer | – | – | Sep 24, 2025 |
| Eugene Williams | Director | 40,213 | 0.45% | Nov 6, 2026 |
| Josh Mandel-Brehm | Director | – | – | May 22, 2026 |
| Madge K. Shafmaster | Director | 208,333 | 2.32% | May 22, 2026 |
| Slanix Paul Alex | Director | 6,058,738 | 67.56% | May 22, 2026 |
| William W. Wyman | Director | 62,937 | 0.70% | May 22, 2026 |
| Patrick D. Kirwin | Director | 10,093 | 0.11% | Apr 23, 2026 |
| Global Life Science Capital Partners V. GP Ltd ABG | 10% owner | – | – | Feb 25, 2026 |
| Ally Bridge Group Global Life Science Capital Partners V, L.P. | 10% owner | – | – | Feb 25, 2026 |
| V-SIV IX Ltd ABG | 10% owner | – | – | Feb 25, 2026 |
| V-SIV X. Ltd ABG | 10% owner | – | – | Feb 25, 2026 |
| ABG Global Life Science Capital Partners V GP, L.P. | 10% owner | 943,090 | 10.52% | Feb 25, 2026 |
| Fan Yu | 10% owner | 943,090 | 10.52% | Feb 5, 2026 |
| Management Ltd. ABG | 10% owner | – | – | Feb 5, 2026 |
| Bridge Group (NY) LLC Ally | 10% owner | – | – | Feb 5, 2026 |
| Bridge MedAlpha Master Fund L.P. Ally | 10% owner | 6,058,738 | 67.56% | Feb 5, 2026 |
| M. Sclar 2012 Irrevocable Family Trust Jeremy | 10% owner | 1,617,437 | 18.04% | Sep 30, 2025 |
| Jeremy M. Sclar | 10% owner | 7,246,296 | 80.80% | Sep 8, 2025 |
| 19 Promis Title | – | 2,435,029 | 27.15% | Aug 14, 2025 |
| Jonathan Shafmaster | 10% owner | – | – | Aug 14, 2025 |
| QIC LLC Shaf | 10% owner | 5,184,760 | 57.82% | Aug 14, 2025 |
| Michael S. Gordon | – | 2,435,029 | 27.15% | Aug 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eugene Williams Director | Nov 4, 2026 | Buy | +26,500 | $3.43 | $90.90K | 40,213 |
| Neil Cashman Chief Scientific Officer, Director | Nov 2, 2026 | Buy | +10,000 | $3.86 | $38.60K | 14,532 |
| Eugene Williams Director | Oct 30, 2026 | Buy | +1,316 | $3.99 | $5.25K | 13,713 |
| Johanne Kaplan Chief Development Officer | Aug 5, 2026 | Buy | +2,280 | $13.30 | $30.32K | 6,221 |
| Patrick D. Kirwin Director | Apr 22, 2026 | Buy | +4,000 | $11.33 | $45.32K | 4,653 |
| Eugene Williams Director | Mar 5, 2026 | Buy | +2,000 | $24.40 | $48.80K | 12,397 |
| Eugene Williams Director | Mar 4, 2026 | Buy | +2,000 | $24.00 | $48.00K | 10,397 |
| Eugene Williams Director | Mar 3, 2026 | Buy | +1,000 | $21.89 | $21.89K | 8,397 |
| Eugene Williams Director | Mar 2, 2026 | Buy | +1,000 | $22.53 | $22.53K | 7,397 |
| Johanne Kaplan Chief Development Officer | Feb 19, 2026 | Buy | +1,629 | $15.35 | $25.01K | 3,941 |
| Max A. Milbury – | Feb 3, 2026 | Award | +6,595 | $12.13 | $80.00K | 8,409 |
| Johanne Kaplan Chief Development Officer | Feb 3, 2026 | Award | +2,060 | $12.13 | $24.99K | 2,312 |
| Neil Cashman Chief Scientific Officer, Director | Feb 3, 2026 | Award | +4,122 | $12.13 | $50.00K | 4,122 |
| Patrick D. Kirwin Director | Feb 3, 2026 | Award | +3,050 | $12.13 | $37.00K | 5,135 |
| Neil K. Warma Chief Executive Officer, Director | Feb 3, 2026 | Award | +6,183 | $12.13 | $75.00K | 6,183 |
| Fan Yu 10% owner | Feb 3, 2026 | Buy | +700,741 | $12.13 | $8.50M | 943,090 |
| Max A. Milbury – | Oct 3, 2025 | Buy | +30,392 | $0.49 | $14.89K | 45,389 |
| M. Sclar 2012 Irrevocable Family Trust Jeremy 10% owner | Jul 25, 2025 | Option exercise | +697,674 | – | – | 3,012,785 |
| M. Sclar 2012 Irrevocable Family Trust Jeremy 10% owner | Jul 25, 2025 | Option exercise | +697,674 | – | – | 2,315,111 |
| M. Sclar 2012 Irrevocable Family Trust Jeremy 10% owner | Jul 25, 2025 | Option exercise | +697,674 | – | – | 3,710,459 |
| Jeremy M. Sclar 10% owner | Jul 25, 2025 | Option exercise | +697,674 | – | – | 3,710,459 |
| Jeremy M. Sclar 10% owner | Jul 25, 2025 | Option exercise | +697,674 | – | – | 2,315,111 |
| Jeremy M. Sclar 10% owner | Jul 25, 2025 | Option exercise | +697,674 | – | – | 3,012,785 |
| 19 Promis Title 10% owner | Jul 25, 2025 | Option exercise | +119,800 | – | – | 2,435,029 |
| 19 Promis Title 10% owner | Jul 25, 2025 | Option exercise | +119,800 | – | – | 2,315,229 |
| 19 Promis Title 10% owner | Jul 25, 2025 | Option exercise | +119,800 | – | – | 2,195,429 |
| Michael S. Gordon 10% owner | Jul 25, 2025 | Option exercise | +119,800 | – | – | 2,315,229 |
| Michael S. Gordon 10% owner | Jul 25, 2025 | Option exercise | +119,800 | – | – | 2,195,429 |
| Michael S. Gordon 10% owner | Jul 25, 2025 | Option exercise | +119,800 | – | – | 2,435,029 |
| Michael S. Gordon 10% owner | Jun 30, 2025 | Sale | −93,223 | – | – | 0 |
| Michael S. Gordon – | Mar 13, 2025 | Other | −48,333 | – | – | 0 |
| Neil Cashman Chief Scientific Officer, Director | Feb 10, 2025 | Buy | +15,000 | $0.97 | $14.55K | 16,617 |
| Madge K. Shafmaster Director | Sep 24, 2024 | Buy | +70,000 | $1.30 | $91.00K | 208,333 |
| Madge K. Shafmaster Director | Sep 23, 2024 | Buy | +70,000 | $1.28 | $89.60K | 138,333 |
| Madge K. Shafmaster Director | Sep 20, 2024 | Buy | +60,000 | $1.25 | $75.00K | 68,333 |
| Michael S. Gordon 10% owner | Sep 17, 2024 | Buy | +16,292 | $1.40 | $22.81K | 93,223 |
| Michael S. Gordon 10% owner | Sep 16, 2024 | Buy | +76,931 | $1.22 | $93.86K | 76,931 |
| Patrick D. Kirwin Director | Aug 14, 2024 | Buy | +10,000 | $1.25 | $12.50K | 62,983 |
| 19 Promis Title 10% owner | Jul 31, 2024 | Buy | +465,116 | – | – | 1,575,629 |
| 19 Promis Title 10% owner | Jul 31, 2024 | Conversion | +500,000 | – | – | 2,075,629 |
| Jeremy M. Sclar 10% owner | Jul 31, 2024 | Conversion | +150,000 | – | – | 1,155,726 |
| Jeremy M. Sclar 10% owner | Jul 31, 2024 | Buy | +697,674 | – | – | 1,467,437 |
| Jeremy M. Sclar 10% owner | Jul 31, 2024 | Conversion | +150,000 | – | – | 1,617,437 |
| Michael S. Gordon 10% owner | Jul 31, 2024 | Conversion | +500,000 | – | – | 2,075,629 |
| Michael S. Gordon 10% owner | Jul 31, 2024 | Buy | +465,116 | – | – | 1,575,629 |
| Max A. Milbury Principal Accounting Officer | Aug 23, 2023 | Award | +13,297 | – | – | 14,997 |
| Gavin T. Malenfant Chief Operating Officer | Aug 23, 2023 | Award | +2,660 | – | – | 2,660 |
| Neil Cashman Chief Scientific Officer, Director | Aug 23, 2023 | Award | +10,643 | – | – | 113,304 |
| Patrick D. Kirwin Director | Aug 23, 2023 | Award | +11,000 | – | – | 52,983 |
| Gail M. Farfel Chief Executive Officer, Director | Aug 23, 2023 | Award | +53,192 | – | – | 55,192 |
| Eugene Williams Director | Dec 16, 2022 | Buy | +1,000 | $4.64 | $4.64K | 159,930 |
| Eugene Williams Director | Dec 16, 2022 | Buy | +1,000 | $4.65 | $4.65K | 158,930 |
| Patrick D. Kirwin Director | Dec 15, 2022 | Buy | +2,000 | $4.51 | $9.02K | 27,998 |
| Gail M. Farfel Chief Executive Officer | Dec 14, 2022 | Buy | +1,000 | $4.94 | $4.94K | 2,000 |
| Patrick D. Kirwin Director | Dec 13, 2022 | Buy | +1,000 | $4.87 | $4.87K | 25,998 |
| Eugene Williams Director | Dec 12, 2022 | Buy | +1,000 | $5.08 | $5.08K | 157,930 |
| Patrick D. Kirwin Director | Dec 9, 2022 | Buy | +1,000 | $4.98 | $4.98K | 24,998 |
| Eugene Williams Director | Dec 7, 2022 | Buy | +1,000 | $5.49 | $5.49K | 156,930 |
| Gail M. Farfel Chief Executive Officer | Dec 6, 2022 | Buy | +1,000 | $5.70 | $5.70K | 1,000 |
| Eugene Williams Director | Dec 2, 2022 | Buy | +1,000 | $5.98 | $5.98K | 155,930 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ProMIS Neurosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,804 shares on Sep 10, 2026 over the last 90 days.
See a number that looks wrong?